Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Incyte Corp. (Nasdaq: INCY) say a treatment for patients with a certain type of dermatitis showed positive results in a Phase 2 study. Last month, the companies also announced plans to resubmit baricitinib to the U.S. Food and Drug Administration for the treatment of rheumatoid arthritis.
In April, the FDA rejected the New Drug Application for baricitinib as a once-daily treatment for rheumatoid arthritis, saying it needed more clinical results. The European Union approved the treatment in February.
The most recent study showed the drug, in combination with another treatment, "significantly improved" the signs and symptoms of moderate-to-severe atopic dermatitis. The trial involved 16 weeks of treatment, with 61 percent of patients receiving the treatment achieving a 50 percent or greater reduction in the overall severity of the condition.
The companies presented the results today at the European Academy of Dermatology and Venereology Annual Meeting in Switzerland.